- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02322853
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors (OLYMPE)
A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Metastatic breast cancer (MBC) remains an incurable disease and despite an improvement of the effect of systemic treatments. After relapse on first-line non-steroidal aromatase inhibitor, current clinical practice and treatment guidelines include tamoxifen, fulvestrant (an ER antagonist) and exemestane as available options (NCCN treatment guidelines 2012), but in this context of resistance, their efficacy are poor.
Some results confirm the possibility to improve the efficacy of tamoxifen in metastatic setting by a combination with therapy targeting signal transduction pathways. Other transduction pathways seem to be involved in endocrine sensitivity/resistance, such as RAS/RAF/MEK/MAK pathway.
LY2228820 inhibits the activity of p38 MAPK (selective inhibitor of the α and β isoforms of p38 MAPK in vitro) and reduces phosphorylation of its cellular target, MAPK-activated protein kinase 2 (MAPKAP-K2).
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Bordeaux, 프랑스
- Institut Bergonié
-
Caen, 프랑스
- Centre Francois Baclesse
-
Clermont -Ferrand, 프랑스
- Centre Jean Perrin
-
Dijon, 프랑스
- Centre Georges-François Leclerc
-
Lyon, 프랑스
- Centre Leon Berard
-
Marseille, 프랑스
- Institut Paoli Calmettes
-
Nantes, 프랑스
- Institut de Cancérologie de l'Ouest
-
Paris, 프랑스
- Hegp, Ap-Hp
-
Paris, 프랑스
- Hôpital St Louis, AP-HP
-
Rennes, 프랑스
- Centre Eugène Marquis
-
Rouen, 프랑스
- Centre Henri Becquerel
-
St Cloud, 프랑스
- Institut Curie
-
Toulouse, 프랑스
- Institut Claudius Regaud
-
Villejuif, 프랑스
- Institut Gustave Roussy
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Women with histologically confirmed breast cancer
- 18 < age < 80 years old
Menopausal status Women are considered post-menopausal and not of child bearing potential if they have had
- 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or
- 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or
- surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
- ER-positive status by local laboratory testing (>10% by IHC) and HER2-negative status (IHC 0 or 1+ or 2+ and FISH negative) on the last biopsy or surgical specimen available.
- Disease progression defined as inoperable locally advanced or metastatic breast cancer (MBC) excluding aggressive visceral disease requiring other approaches, such as chemotherapy
Disease refractory to aromatase inhibitors (AI) defined as:
- recurrence while on, or within 12 months of end of adjuvant treatment with aromatase inhibitor, or
- progression while on, or within 3 months of end of AI for locally advanced or MBC
- Patients who have received fulvestrant are eligible
- Maximum 2 previous lines of chemotherapy for MBC
- Performance Status (PS) ≤ 2
- Patient able to swallow and retain oral medication
Measurable or evaluable lesions as per RECIST 1.1
- Measurable disease (≥ 20 mm by conventional techniques or ≥ 10 mm by spiral computed tomography scan) or
- Non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.
- Patients with only pleural effusion and/or ascites are not eligible.
Adequate bone marrow and organ function as defined by the following laboratory values:
- Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
- Platelets (plt) ≥ 100 x 109/L
- Hemoglobin (Hgb) ≥ 9 g/dl
- INR ≤ 1.5 without any anticoagulation treatment
- Serum creatinine ≤ 1.5 x ULN
- Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) within normal range (or < 3.0 x ULN if liver metastases are present)
- Total serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from CBC count (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosis
- Patient has signed informed consents obtained before any trial related activities and according to local guidelines
Exclusion Criteria:
• Previous treatment with p38 MAPK inhibitors or Tamoxifen in metastatic setting (adjuvant treatment by tamoxifen is allowed)
- More than 2 lines of chemotherapy for locally advanced and/or metastatic breast cancer
- Brain metastasis
- Other malignancy (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer).
- Clinically significant (i.e. active) cardiovascular disease: cerebro-vascular accident/stroke or myocardial infarction within 6 months prior to first study medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or higher; or serious cardiac arrhythmia requiring medication.
- Have had a major bowel resection that would alter oral drug absorption.
- Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Are receiving concurrent administration of immunosuppressive therapy
- Concurrent participation in any therapeutic clinical trial
- Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: TAMOXIFEN
Tamoxifen will be administered daily orally Patients will receive study medication until disease progression or unacceptable toxicity |
hormonotherapy
|
실험적: TAMOXIFEN + LY2228820
Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally Patients will receive study medication until disease progression or unacceptable toxicity |
hormonotherapy
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
To define the efficacy (progression-free survival rate at 6 months) of LY2228820 in combination with tamoxifen for postmenopausal women with an ER positive and HER2 negative advanced or metastatic breast cancer who progressed on aromatase inhibitors.
기간: at 6 months after treatment start.
|
at 6 months after treatment start.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
- To evaluate the toxicity profile (Safety and Tolerability) of the LY2228820 in combination with tamoxifen
기간: From date of randomization until study participation (during average 12 months)
|
Adverse events description and grade in all participants
|
From date of randomization until study participation (during average 12 months)
|
- To estimate the Progression-Free Survival of the LY2228820 in combination with tamoxifen
기간: evaluated every 8-12 weeks (during average 12 months)
|
evaluated every 8-12 weeks (during average 12 months)
|
|
- To assess the overall survival of the LY2228820 in combination with tamoxifen
기간: From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months
|
From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months
|
|
- To assess response duration of the LY2228820 in combination with tamoxifen
기간: evaluated every 8-12 weeks during treatment to progression or death for any cause.(during average 12 months)
|
evaluated every 8-12 weeks during treatment to progression or death for any cause.(during average 12 months)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Christelle LEVY, MD, c.levy@baclesse.unicancer.fr
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- OLYMPE / 2013-005084-29
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
전이성 유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
Tamoxifen에 대한 임상 시험
-
NRG OncologyNational Cancer Institute (NCI)모병
-
CHU de Quebec-Universite LavalGlaxoSmithKline완전한
-
Sanofi모집하지 않고 적극적으로유방암 전이성대한민국, 벨기에, 대만, 중국, 프랑스, 미국, 아르헨티나, 호주, 브라질, 캐나다, 체코, 그리스, 이스라엘, 이탈리아, 일본, 라트비아, 멕시코, 폴란드, 푸에르토 리코, 러시아 연방, 스페인, 칠면조, 우크라이나